Good morning :)
Place Order
Add to Watchlist

Bajaj Healthcare Ltd

BAJAJHCARE

Bajaj Healthcare Ltd

BAJAJHCARE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,247 cr, stock is ranked 1,372
Moderate RiskStock is 2.86x as volatile as Nifty
395.100.01% (-0.05)
395.100.01% (-0.05)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,247 cr, stock is ranked 1,372
Moderate RiskStock is 2.86x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,247 cr, stock is ranked 1,372
Moderate RiskStock is 2.86x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-43.894.480.22%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of bulk drugs and pharmaceutical products. The Company's segments include manufacturing of Bulk Drugs, and Formulation and sale of medicines.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 5.37%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.17% to 0.13%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue223.22233.04329.18371.14416.54663.89681.33647.39482.11487.33
Raw Materialssubtract128.77131.50215.43245.33268.32377.19409.91393.84264.43458.43
Power & Fuel Costsubtract14.1216.7919.8121.8324.2424.9631.8337.6931.47
Employee Costsubtract16.9319.5721.6524.6228.1834.5541.1142.3243.85
Selling & Administrative Expensessubtract6.015.685.687.318.0012.9114.8614.8616.21
Operating & Other expensessubtract26.9626.2825.1028.1632.9871.0063.5266.11154.92
Depreciation/Amortizationsubtract9.2911.3511.0811.4112.1216.1217.6417.2127.6228.04
Interest & Other Itemssubtract7.648.207.738.326.638.3412.7817.6829.7529.36
Taxes & Other Itemssubtract5.295.877.507.8610.8235.7118.3014.65-2.35-0.07
EPS2.281.432.752.954.5715.0617.2415.59-30.36-10.30
DPS0.000.000.250.000.001.381.501.001.001.00
Payout ratio0.000.000.090.000.000.090.090.06-0.10

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Aug 18PDF
FY 2022

Annual report

PDF

Investor Presentation

Jun 27PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Bajaj Healthcare Ltd-14.894.480.22%
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare BAJAJHCARE with any stock or ETF
Compare BAJAJHCARE with any stock or ETF
BAJAJHCARE
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 8.55%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 1.06%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding59.19%1.31%0.66%1.07%37.78%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.69%0.66%0.74%0.53%0.01%1.07%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.31%

Top 1 Mutual Funds holding Bajaj Healthcare Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Pharma and Healthcare Fund - Growth - Direct Plan

Growth
1.1588%1.08%1.08%35/39 (+4)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateSep 22, 2023

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 22, 2023

Cash Dividend

Ex DateEx DateSep 22, 2022

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 22, 2022

Cash Dividend

Ex DateEx DateSep 28, 2021

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 28, 2021

Cash Dividend

Ex DateEx DateSep 28, 2021

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 28, 2021

News & Opinions
Corporate
Bajaj Healthcare enters into API development and supply agreement with European company

Bajaj Healthcare has entered into a development and supply agreement for an Active Pharmaceutical Ingredient (API) with a European entity. This API after its development will be initially supplied in small quantities and will be used by the EU partner to carry out clinical trials for an alternative indication. Based on the outcome of these trials, the supplies will be done from the Company's FDA approved manufacturing facility situated at Savli, Vadodara.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Bajaj Healthcare gains on inking pact with European entity

After the development, the API will be initially supplied in small quantities and will be used by the EU partner to carry out clinical trials for an alternative indication. The trust reposed in the company by the EU partner for sourcing clinical trial quantities is a testimony of the company's development and manufacturing capabilities along with the good manufacturing practices (GMP) compliance at company's manufacturing units. Based on the outcome of these trials, the supplies will be done from the company's FDA approved manufacturing facility situated at Savli, Vadodara. Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America. The company's standalone net profit jumped 14.1% to Rs 8.02 crore in Q1 FY25 as against 7.03 crore recorded in Q1 FY24. Revenue from operations increased 1.9% YoY to Rs 132.25 crore in Q1 FY25.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Bajaj Healthcare approves preferential allotment of shares and warrants

The Board of Bajaj Healthcare at its meeting held on 19 September 2024 has approved the allotment of 39,84,852 equity shares of the Company of face value of Rs. 5/- each fully paid at a price of Rs. 338/-, (including a premium of Rs. 333/- per equity share) aggregating to Rs. 1,34,68,79,976/-. The board has also approved allotment of 20,79,409 fully convertible warrants with each warrant convertible into or exchangeable for One (1) fully paid-up equity share of the Company of face value of Rs. 5/- each at an issue price of Rs. 338/-(including a premium of Rs. 333/-) per warrant, aggregating to Rs. 70,28,40,242/- to the Promoter, Promoter Group and Persons belonging to Non-Promoter category on Preferential Basis. Consequent to the aforesaid allotment of Equity Shares, the paid-up equity share capital of the Company stands increased to Rs. 15,79,16,260 comprising of 3,15,83,252 equity shares of the face value of Rs. 5/- each.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Bajaj Healthcare schedules AGM

Bajaj Healthcare announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Bajaj Healthcare announces board meeting date

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 19 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Bajaj Healthcare reports standalone net profit of Rs 7.13 crore in the June 2024 quarter

Net profit of Bajaj Healthcare reported to Rs 7.13 crore in the quarter ended June 2024 as against net loss of Rs 48.21 crore during the previous quarter ended June 2023. Sales rose 1.93% to Rs 132.25 crore in the quarter ended June 2024 as against Rs 129.74 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales132.25129.74 2 OPM %18.5316.76 - PBDT16.9113.22 28 PBT10.186.91 47 NP7.13-48.21 LP Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Bajaj Healthcare schedules board meeting

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Bajaj Healthcare Shares Soar 16% On API Deals With U.K., EU Clients

8 months agoBloomberg Quint

Stocks to watch on June 30, 2023

1 year agoThe Hindu Businessline

Sensex dives over 500 points: Rs 1.25L cr investor wealth lost; KRBL, Rhi Magnesita & Campus Activewear down up to 9%

1 year agoBusiness Today